Shares of Erasca Inc. (ERAS) touched a 52-week high of $24.28 during intraday trading yesterday, as the company gears up for clinical data readouts of its lead drug candidate ERAS-0015.
ERAS-0015 is a pan-RAS molecular glue designed to target RAS proteins in their active (GTP-bound) state. By doing so, it can block the signaling pathways driven by both mutant and normal RAS, potentially stopping cancer cell growth. The RAS pathway is implicated in multiple cancers.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.